- Home
- JAZZ vs LLYVK Comparison
JAZZ vs LLYVK Comparison
Compare JAZZ & LLYVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- LLYVK
- Stock Information
- Founded
- JAZZ 2003
- LLYVK 1991
- Country
- JAZZ Ireland
- LLYVK United States
- Employees
- JAZZ N/A
- LLYVK N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- LLYVK Broadcasting
- Sector
- JAZZ Health Care
- LLYVK Industrials
- Exchange
- JAZZ Nasdaq
- LLYVK Nasdaq
- Market Cap
- JAZZ 6.1B
- LLYVK 6.7B
- IPO Year
- JAZZ 2007
- LLYVK N/A
- Fundamental
- Price
- JAZZ $97.78
- LLYVK $75.08
- Analyst Decision
- JAZZ Strong Buy
- LLYVK
- Analyst Count
- JAZZ 13
- LLYVK 0
- Target Price
- JAZZ $181.85
- LLYVK N/A
- AVG Volume (30 Days)
- JAZZ 1.3M
- LLYVK 302.6K
- Earning Date
- JAZZ 05-06-2025
- LLYVK 01-01-0001
- Dividend Yield
- JAZZ N/A
- LLYVK N/A
- EPS Growth
- JAZZ 49.21
- LLYVK N/A
- EPS
- JAZZ 7.51
- LLYVK N/A
- Revenue
- JAZZ $4,064,808,000.00
- LLYVK N/A
- Revenue This Year
- JAZZ $7.60
- LLYVK $7.29
- Revenue Next Year
- JAZZ $3.47
- LLYVK N/A
- P/E Ratio
- JAZZ $13.00
- LLYVK N/A
- Revenue Growth
- JAZZ 5.76
- LLYVK N/A
- 52 Week Low
- JAZZ $95.49
- LLYVK $33.50
- 52 Week High
- JAZZ $148.06
- LLYVK $81.66
- Technical
- Relative Strength Index (RSI)
- JAZZ 33.01
- LLYVK 62.14
- Support Level
- JAZZ $97.50
- LLYVK $69.60
- Resistance Level
- JAZZ $120.67
- LLYVK $75.53
- Average True Range (ATR)
- JAZZ 4.33
- LLYVK 1.98
- MACD
- JAZZ -0.53
- LLYVK 0.46
- Stochastic Oscillator
- JAZZ 1.21
- LLYVK 91.51
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.